NEWS
Takehiko Kaneko, CMO and Head of R&D at Heartseed, is speaking at this year's Next Generation Cardiovascular Drug Development in April 25-27.
Takehiko Kaneko, CMO and Head of R&D at Heartseed, is speaking at this year's Next Generation Cardiovascular Drug Development in April 25-27, presenting " Purification & Differentiation for Clinical Use of iPSC Derived Cardiomyocytes".
Following technology advancements and the surge of investment in developing the next generation of cardiovascular disease drugs, the opportunity to successfully leverage our knowledge of CRISPR/Cas9, siRNA, autologous iPSC therapy, capsid engineering, and digital medicine to reduce the soaring fatality rate has never been closer.
The Next Generation Cardiovascular Drug Development Summit in Boston is the only industry-led summit committed to overcoming preclinical challenges to advance your ischemic heart disease, arrhythmogenic cardiomyopathy, strokes and hypertension pipelines.
April 27, 11:00 am VIRTUAL Exploring Strategies to Align Manufacturing of Stem Cell Derived Products to the Safety & Efficacy of the Product Whilst Meeting CMC Requirements
- Illustrating ways to generate high-quality induced pluripotent stem cells (iPSCs)
- Understanding the specific differentiation into ventricular cardiomyocytes to minimize safety risks of the cells
- Establishing a scalable manufacturing system to purify cardiomyocytes and reduce the cost of goods